Tengion Inc

Tengion — Investor Presentation (May 2012)

28 slides from Tengion's investor presentation, May 10, 2012

  1. Slide 1: Regenerative medicine brought to life

    Regenerative medicine brought to life ® May 2012 Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its know

  3. Slide 3: Delivering Organ Regeneration

    Delivering Organ Regeneration Novel technology platform that: • Utilizes selected populations of regenerative cells • Harness these cells to create specific neo-organs • Has the potential to produce these neo-organs on a commercial scale

  4. Slide 4: Anticipated Benefits of Our Regenerative Medicine Platform

    Anticipated Benefits of Our Regenerative Medicine Platform • Regenerate native-like function and structure • Reduce healthcare costs for organ failure while improving medical outcomes – Avoid the risk of organ rejection – Eliminate the burden and costs of immunosuppression • Provide meaningful clini

  5. Slide 5: Investment Highlights

    Investment Highlights • Biotechnology company focused on tissue and organ regeneration using a patient’s own cells – Strong IP, know-how, and trade secrets around core process • Neo-Urinary Conduit TM : our goal is to improve upon standard of care for bladder cancer patients requiring cystectomy – C

  6. Slide 6: Neo-Urinary Conduit

    Neo-Urinary Conduit

  7. Slide 7: Neo-Urinary Conduit: Large Market Opportunity

    Neo-Urinary Conduit: Large Market Opportunity Estimated 2012 Urinary Diversion Surgical Procedures* 13,100 15,200 *L.E.K. and company estimates Number of procedures growing at ~3% per annum

  8. Slide 8: Our Neo-Urinary Conduit Offers Advantages

    Our Neo-Urinary Conduit Offers Advantages • Potentially shorter, less complex and standardized surgical procedure • Improved recovery times • Avoids side effects associated with bowel tissue resection and urine absorption ₋ Infection ₋ Excess mucus formation ₋ Cancer

  9. Slide 9: Positive Initial Payer Comments

    Positive Initial Payer Comments • Payers believe a $40,000 price for Neo-Urinary Conduit is reasonable • Incremental cost savings – Reduction is surgery and hospitalization time – Reduction in complications – Quality of life improvements • Limited incremental exposure per payer • Older population li

  10. Slide 10: Tengion's Neo-Urinary Conduit

    Tengion’s Neo-Urinary Conduit • Regenerates native-like urinary tissue with no bowel resection or urine absorption- related metabolic disorders • Created using patient’s own cells – Cells obtained from simple fat biopsy – Cells grown and placed on biodegradable scaffold – Implanted at time of cystec

  11. Slide 11: Neo-Urinary Conduit vs. Standard of Care

    Neo-Urinary Conduit vs. Standard of Care Non-Continent Urinary Diversion Conduit Neo-Urinary Conduit

  12. Slide 12: Phase Trial Overview

    Phase 1 Trial Overview • Open label study to define surgical procedure and safety • Preliminary efficacy assessment: Structural integrity and conduit patency at 1 year post implant • Will enroll up to 10 patients with primary bladder cancer requiring cystectomy • Expect to complete enrollment by the

  13. Slide 13: Phase Trial Progress: Translation and Regeneration

    Phase 1 Trial Progress: Translation and Regeneration • Four of 10 patients enrolled so far • Results from patients 1-3 provided a framework for an updated procedure for the fourth patient – Ureteral attachment utilizes a widely accepted procedure – Modified stoma ostomy to improve stoma patency – Va

  14. Slide 14: Next Steps for the Neo-Urinary Conduit

    Next Steps for the Neo-Urinary Conduit • Expect to implant the 10 th patient by the end of 2012 – Anticipate one-year data available for all patients during 4Q 2013 • Begin phase 2/3 clinical trial during 2H 2013 – Randomized, non-blinded 2-arm trial – N = 250-300 (150 NUC vs 100-150 standard of car

  15. Slide 15: Neo-Kidney Augment

    Neo-Kidney Augment

  16. Slide 16: Neo-Kidney Augment Market Opportunity

    Neo-Kidney Augment Market Opportunity • Intended to prevent or delay the need for dialysis or transplantation • An estimated 26 million adults in the United States have chronic kidney disease (CKD) – 100,000 new dialysis patients each year in the US – 350,000 currently on dialysis – 20% annual morta

  17. Slide 17: Tengion's Neo-Kidney Augment

    Tengion’s Neo-Kidney Augment • Intended to prevent or delay dialysis or kidney transplantation by increasing renal function in patients with advanced CKD – Neo-Kidney Augment may catalyze the regeneration of functional kidney tissue • Utilizes a patient’s own renal cells – Obtained by needle biopsy

  18. Slide 18: Efficient and Scalable Manufacturing Process

    Efficient and Scalable Manufacturing Process

  19. Slide 19: Robust Preclinical Data for Neo-Kidney Augment

    Robust Preclinical Data for Neo-Kidney Augment • Significant effects in aggressive rodent models of diabetic kidney failure and CKD - results published in top-tier journals – Diabetic kidney failure model • Uncontrolled diabetic, obese, hypertensive rodent model of kidney failure • Slowed kidney dis

  20. Slide 20: Regenerative Cells Improve Kidney Function and Extend Survival

    Regenerative Cells Improve Kidney Function and Extend Survival ZSF1 Groups 1-Year Survival Untreated 20% (1/5) OB ZSF1 + NKA 100% (5/5) Renal Cells improve kidney function over time Effects beyond 1 year of age in renal diseased diabetic rat Renal Cells support survival beyond 50% mortality time poi

  21. Slide 21: Human Kidney Tissue Regeneration in Nude Rats

    Human Kidney Tissue Regeneration in Nude Rats Human-derived cells prevent renal failure in CKD Nude Rats for 3 months Human-derived cells improve CKD Nude Rat nephron function Delayed progression of CKD and stabilized renal function *

  22. Slide 22: Multiple Mechanisms of Action in CKD

    Multiple Mechanisms of Action in CKD • Implanted regenerative cells persist for at least 6 months • Regeneration of functional renal tissue - Regenerative and resident cells regenerate, replace and repair renal structures post-implantation • Attenuation of inflammatory and fibrosis pathways - Molecu

  23. Slide 23: Next Steps for Neo-Kidney Augment

    Next Steps for Neo-Kidney Augment • Commence GLP studies to support U.S. IND filing in 1H 2013 – 6 month ZSF1 rat study (diabetic kidney failure) – 3 month canine safety study – 6 month repeat dose canine study • Parallel track European approach – Define pathway during 2H 2012 to European First-in-H

  24. Slide 24: Significant IP and Barriers to Entry

    Significant IP and Barriers to Entry • Technology protected by issued patent protection plus recent applications pending — 28 U.S. and 97 international patents and patent applications for regeneration of multiple organs and tissues — Core patents cover composition, design and methods of manufacture*

  25. Slide 25: Corporate

    Corporate

  26. Slide 26: Financial Overview and Current Stockholders

    Financial Overview and Current Stockholders March 31, 2012 Cash and Investments Long-Term Debt Adjusted Net Loss Shares Outstanding * December 31, 2011 $8.9 M $4.5 M $4.1 M 24.5 M $15.3 M $5.0 M $19.1 M 23.8 M Current cash expected to last until September 2012 * Potential for reverse stock split in

  27. Slide 27: Upcoming Milestones

    Upcoming Milestones Milestone Expected Neo-Urinary Conduit Complete enrollment of phase 1 clinical trial End of 2012 Initiate phase 2/3 study 2H 13 Obtain 1-year data from phase 1 clinical trial 2H 13 Neo-Kidney Augment Define European regulatory pathway 2H 12 IND filing 1H 13

  28. Slide 28: Investment Highlights

    Investment Highlights • Biotechnology company focused on tissue and organ regeneration using a patient’s own cells – Strong IP, know-how, and trade secrets around core process • Neo-Urinary Conduit TM : our goal is to improve upon standard of care for bladder cancer patients requiring cystectomy – C

Tengion — Investor Presentation (May 2012) on 6ix